Entecavir Combined Ganpi ? Paste Treatment To Stagnation Of Liver Qi And Spleen Deficiency And Phlegm Dampness Type Of Chronic Hepatitis B With Nonalcoholic Fatty Liver Disease Clinical Observation

Objective:“GanPi ?” Paste is experience in the therapy of stagnation of liver qi and spleen deficiency and phlegm dampness type of nonalcoholic fatty liver disease.The purpose of this study is to explore entecavir combined“GanPi ?”paste for the treatment of chronic hepatitis B combined clinical efficacy and safety of nonalcoholic fatty liver disease.Methods:According to the inclusion criteria,exclusion criteria selection of 60 cases of type liver qi and spleen deficiency and phlegm dampness in patients with chronic hepatitis B with nonalcoholic fatty liver disease,USES the computer random grouping,divided into control group,30 cases in treatment group 30 cases.Above two groups of patients in the general foundation treatment and oral entecavir tablet(brand name Baraclude referred to as “Bo Lu Ding”,the production in the sino-american Shanghai squibb company 0.5 mg/pill)daily on an empty stomach oral,0.5 mg qd.Treatment group on the control scheme combined “GanPi ?” Paste,taking three times a day,10 g each time,warm water blunt.A course of 24 weeks.Were observed before and after treatment of two groups of patients with HBV-DNA loads,alanine aminotransferase,aspartate aminotransferase,total cholesterol,triglyceride,body weight,body mass index,ventral ultrasound and clinical symptom integral change and adverse drug reactions.The collected data through statistical analysis of statistical software SPSS19 clinical effectiveness and safety evaluation in the two groups.Result:1.24 weeks after treatment,Two group total effective rate of 83.33%,93.33% respectively,the difference is statistically significant(P< 0.05).2.After 12 weeks of treatment,HBV-DNA overcast rate between the two groups was no significant difference(P>0.05),24 weeks after treatment,two groups of HBV-DNA overcast rate comparison,the treatment group is better than that of control group,the difference was statistically significant(P< 0.05).3.After 12 weeks of treatment,the control group and treatment group of antiviral response rates were 40%,60%;Treatment at 24 weeks,the control group and treatment group of antiviral response rate was86.67%,the treatment group was 100%,the contrast between the two groups was statistically significant difference(P<0.05).4.The two groups in the treatment of 12 weeks and 24 weeks after liver function(ALT,AST)before treatment were improved,the difference was statistically significant(P<0.05),in 24 weeks after treatment,the comparison between the two groups,the treatment group is better than that of control group,the difference was statistically significant(P<0.01).5.Compare two groups of TC,TG levels,12 weeks and 24 weeks after treatment,the comparison is,in the way and there was no statistically significant difference(P>0.05).The treatment group significantly lower TC and TG levels,within the group to compare difference was statistically significant(P<0.05).24 weeks after treatment,the contrast between the two groups was statistically significant difference(P<0.01).6.In 12 weeks after treatment,two groups of curative effect in reducing body weight,body mass index(BMI)were not obvious,comparison between group and group had no statistical significance(P>0.05).In the 24 weeks after treatment,the comparison is difference in the way and has no statistical significance(P>0.05).Treatment within the way comparison,there were significant differences(P<0.05).Comparison between the two groups,the t test(P<0.05),the difference was statistically significant.7.Two groups after treatment in patients with ultrasound results comparison:the control group total effective rate was 80%;Total effective treatment group is 93.33%.The treatment group was better than control group,the difference was statistically significant(P<0.05).8.Twelve weeks after treatment,Through Fibrotouch check(Controlled Attenuation Parametter),Comparison in the group difference was statistically significant(P<0.05)in the treatment way comparative difference was statistically significant(P<0.05);Within 24 weeks after treatment,the two way to compare had statistical significance(P< 0.05),the comparison between the two groups have significant difference(P< 0.001).9.The two groups after treatment for 12 weeks of TCM symptom score were significantly decreased,comparison between groups,group had statistical significance(P<0.05);24 weeks after treatment,the comparison between the two groups have significant difference(P< 0.001).10.Check the related safety indexes before and after the experiment,all within the scope of the security,the treatment group in the process of all the subjects did not appear obvious discomfort,good security.Conclusions:On the basis of general treatment with entecavir tablet combined“GanPi ?” Paste for stagnation of liver qi and spleen deficiency and phlegm dampness in patients with chronic hepatitis B with nonalcoholic fatty liver disease clinical curative effect,compared with single drug entecavir treatment,can significantly increase the rate of HBV-DNA overcast and virological response,at the same time can improve patients related biochemical indicators,and has the advantages in the treatment of nonalcoholic fatty liver disease.